Exelon® helps Alzheimer's disease patients to maintain greater independence
New findings suggest Exelon® significantly reduces decline in performance of activities of daily living in moderate to moderately severe Alzheimer's disease
Basel, 3 April 2003 - Therapy with Exelon (rivastigmine) helps patients with moderate to moderately severe Alzheimer's disease (AD) to maintain greater independence, according to an analysis of nearly 1500 patients.
Please find press release under the following link
Exelon helps Alzheimer's disease patients to maintain greater independence
| Source: Novartis Pharma AG
Attachments
Recommended Reading
-
In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible...
Read More -
Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS Novartis to hold virtual investor event highlighting REMODEL data and...
Read More